Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development

1. Pathios, a biotechnology company, has successfully raised $25 million in a funding round backed by Bristol-Myers Squibb (BMS).
2. The funding will be used to advance the development of Pathios' lead candidate, a GPR65 checkpoint inhibitor, which is a type of cancer immunotherapy.
3. GPR65 is a novel immune checkpoint target that has shown potential in preclinical studies for treating various types of cancer.
4. Checkpoint inhibitors are a class of drugs that block proteins on cancer cells or immune cells, allowing the immune system to recognize and attack cancer cells more effectively.
5. Pathios' GPR65 checkpoint inhibitor aims to improve the efficacy of cancer immunotherapy by targeting a specific pathway that is often exploited by cancer cells to evade the immune system.
6. The investment from BMS, a global biopharmaceutical company, highlights the potential of Pathios' GPR65 checkpoint inhibitor and its significance in the field of cancer immunotherapy.
7. The funding will enable Pathios to further its research and development efforts, bringing the GPR65 checkpoint inhibitor closer to clinical trials and potential commercialization.